Cefixime is NOT recommended as first-line therapy for acute otitis media
Cefixime should be avoided for acute otitis media (AOM) treatment. Multiple French guidelines explicitly state that cefixime is excluded from recommended oral cephalosporins for AOM and respiratory infections in children 1. The 2004 AAP/AAFP guidelines recommend amoxicillin as first-line therapy, with alternative cephalosporins (cefdinir, cefpodoxime, or cefuroxime) for penicillin-allergic patients—notably excluding cefixime from this list 2.
Why Cefixime Falls Short
The primary concern is inadequate coverage against Streptococcus pneumoniae, particularly strains with decreased penicillin susceptibility. French guidelines specifically note that second or third generation oral cephalosporins are acceptable "except cefixime" when treating conditions where pneumococcus is a major pathogen 1. This exclusion is critical because S. pneumoniae causes approximately 47% of AOM cases 3.
While the FDA label indicates cefixime is approved for otitis media 3, and clinical trials showed 69-82% eradication rates for S. pneumoniae 3, this performance is inferior to amoxicillin's 93% eradication rate 4. Research demonstrates cefixime's weakness: it achieved only 75% bacteriologic cure for pneumococcal AOM versus 93% with amoxicillin 4.
What Actually Works
For most children with AOM, prescribe high-dose amoxicillin at 80-90 mg/kg/day 2, 5. This dosing is essential for coverage of resistant pneumococcal strains.
Treatment Algorithm:
Initial therapy:
- First-line: Amoxicillin 80-90 mg/kg/day (divided BID or TID)
- Penicillin allergy (non-Type I): Cefdinir, cefpodoxime, or cefuroxime 2
- Type I hypersensitivity: Consider macrolides or TMP-SMX (though less effective) 2
Treatment failure at 48-72 hours:
- Switch to amoxicillin-clavulanate (90 mg/kg/day of amoxicillin component) 5
- Alternative: Ceftriaxone 50 mg/kg IM for 3 days 5
Duration:
Cefixime's Limited Role
Cefixime demonstrates superior efficacy against H. influenzae (86-100% eradication) compared to amoxicillin (62-68%) 3, 4, 6. However, this advantage doesn't justify its use as monotherapy given the mixed bacterial etiology of AOM.
The only scenario where cefixime appears in guidelines is as part of combination therapy for treatment failures in sinusitis: high-dose amoxicillin or clindamycin PLUS cefixime for dual gram-positive/gram-negative coverage 7. This combination approach is not established for AOM.
Critical Dosing Note
If cefixime were to be used (which is not recommended), the suspension formulation is mandatory for otitis media 3. The FDA label explicitly states tablets/capsules should not substitute for suspension in AOM treatment due to different pharmacokinetics—suspension achieves higher peak blood levels 3. Dosing would be 8 mg/kg/day, given once daily or divided every 12 hours 3.
Common Pitfall
Don't confuse cefixime's FDA approval for otitis media with guideline recommendations. While technically approved, evidence-based guidelines consistently exclude it from recommended regimens due to suboptimal pneumococcal coverage 1. The 10% lower response rate for S. pneumoniae compared to standard therapy is clinically significant 3.